Largest Biotechnology Companies By Total Asset

Total Asset
Total AssetEfficiencyMarket RiskExp Return
1ABBV AbbVie Inc
134.71 B
 0.38 
 0.89 
 0.34 
2AMGN Amgen Inc
97.15 B
 0.02 
 1.39 
 0.03 
3GILD Gilead Sciences
62.12 B
(0.06)
 1.83 
(0.11)
4NERV Minerva Neurosciences
56.9 B
(0.08)
 10.02 
(0.78)
5GMAB Genmab AS
35.29 B
(0.11)
 2.10 
(0.23)
6HLN Haleon Plc
34.81 B
 0.02 
 1.45 
 0.03 
7REGN Regeneron Pharmaceuticals
33.08 B
 0.25 
 1.11 
 0.27 
8BIIB Biogen Inc
26.84 B
(0.05)
 1.70 
(0.08)
9BNTX BioNTech SE
23.28 B
(0.08)
 2.18 
(0.17)
10VRTX Vertex Pharmaceuticals
22.73 B
 0.16 
 2.03 
 0.32 
11GRFS Grifols SA ADR
21.53 B
(0.07)
 5.42 
(0.41)
12MRNA Moderna
18.43 B
 0.08 
 3.94 
 0.31 
13UTHR United Therapeutics
7.17 B
(0.05)
 1.63 
(0.09)
14BMRN Biomarin Pharmaceutical
6.84 B
(0.08)
 1.53 
(0.12)
15INCY Incyte
6.78 B
 0.06 
 2.03 
 0.12 
16EXAS EXACT Sciences
6.47 B
(0.07)
 2.65 
(0.19)
17BGNE BeiGene
5.81 B
(0.03)
 3.30 
(0.10)
18GLPG Galapagos NV ADR
4.73 B
(0.08)
 1.72 
(0.13)
19IMAB I Mab
4.07 B
 0.07 
 6.27 
 0.44 
20ALNY Alnylam Pharmaceuticals
3.83 B
(0.05)
 2.61 
(0.14)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.